Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | NOS3 | P29474 | 1/20 | 0.58 |
| ▸ | NOS1 | P29475 | 1/20 | 0.58 |
| ▸ | NOS2 | P35228 | 1/20 | 0.58 |
| ▸ | THPO | P40225 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | F2 | P00734 | 1/20 | 0.56 |
| ▸ | CFD | P00746 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 6/20 | 0.49 |
| ▸ | MAOB | P27338 | 6/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30908765 | 1.00 | LMNA (0.58) | LMNACYP1A2ADRA2ATSHRNOS3 | |
| SCHEMBL30557808 | 0.85 | LMNA (0.62) | LMNACYP1A2ADRA2ATSHRNOS3 | |
| SCHEMBL625761 | 0.85 | LMNA (0.62) | LMNACYP1A2ADRA2ATSHRNOS3 | |
| SCHEMBL1202291 | 0.78 | NOS1 (0.62) | LMNANOS3NOS1NOS2F2 | |
| SCHEMBL3132671 | 0.78 | MAOA (0.57) | LMNACYP1A2ADRA2ATSHRNOS3 | |
| SCHEMBL694149 | 0.78 | MAOA (0.61) | LMNAF2CFDGAAHPGD | |
| SCHEMBL31460362 | 0.78 | MAOA (0.57) | LMNACYP1A2ADRA2ATSHRNOS3 | |
| SCHEMBL14448380 | 0.78 | F2 (0.56) | LMNACYP1A2ADRA2ATSHRNOS3 | |
| SCHEMBL1147630 | 0.78 | F2 (0.56) | F2CFDMAOAMAOBCA12 | |
| SCHEMBL1668291 | 0.78 | F2 (0.56) | F2CFDGAAMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 883 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118727475-B | Room temperature salt-free rapid reactive dyeing and recycling method suitable for cellulose fibers | 绍兴劲草化工有限公司 | 2025-04-29 | — | — | CN | claimed |
| CN-118727475-A | Room temperature salt-free rapid reactive dyeing and recycling method suitable for cellulose fibers | 绍兴劲草化工有限公司 | 2024-10-01 | — | — | CN | claimed |
| CN-117603144-A | Synthesis method of polysubstituted quinazolinone | 常熟泓德生物科技有限公司 | 2024-02-27 | — | — | CN | claimed |
| CN-110372611-B | Method for selectively synthesizing polysubstituted dihydro quinazolinone or quinazolinone | 常熟理工学院 | 2021-05-04 | — | — | CN | claimed |
| CN-110372611-A | A kind of method of the polysubstituted dihydroquinazoline ketone of selectivity synthesis or quinazolinone | 常熟理工学院 | 2019-10-25 | — | — | CN | claimed |
| US-9580394-B2 | Benzodiazepine derivative and method of producing the same | Atomic Energy Council—Institute of Nuclear Energy Research (TW) | 2017-02-28 | — | — | US | claimed |
| US-20150252009-A1 | BENZODIAZEPINE DERIVATIVE AND METHOD OF PRODUCING THE SAME | ATOMIC ENERGY COUNCIL-INSTITUTE OF NUCLEAR ENERGY RESEARCH (TW) | 2015-09-10 | — | — | US | claimed |
| US-20120009226-A1 | HIGHLY PURE LAQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2012-01-12 | — | — | US | claimed |
| EP-2376456-A2 | HIGHLY PURE LAQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Actavis Group Ptc Ehf (IS) | 2011-10-19 | — | — | EP | claimed |
| US-7772377-B2 | Colorant compositions | XEROX CORPORATION (US) | 2010-08-10 | — | — | US | claimed |
| US-20040215002-A1 | Colorant compositions | XEROX CORPORATION | 2004-10-28 | — | — | US | claimed |
| US-6790267-B1 | METHINE COLORANT COMPOUNDS FOR PHASE CHANGE INKS | XEROX CORPORATION | 2004-09-14 | — | — | US | claimed |
| US-6764541-B1 | Colorant compositions | XEROX CORPORATION | 2004-07-20 | — | — | US | claimed |
| US-6583248-B1 | Methacrylate groups; dental cement | AMERICAN DENTAL ASSOCIATION HEALTH FOUNDATION | 2003-06-24 | — | — | US | claimed |
| US-6180739-B1 | CYCLODEXTRINS WITH ACRYLATE AND ANHYDRIDES | AMERICAN DENTAL ASSOCIATION HEALTH FOUNDATION | 2001-01-30 | — | — | US | claimed |
| US-5929131-A | Polymerizable cyclodextrin derivatives | AMERICAN DENTAL ASSOCIATION HEALTH FOUNDATION (US) | 1999-07-27 | — | — | US | claimed |
| US-5792821-A | Polymerizable cyclodextrin derivatives | AMERICAN DENTAL ASSOCIATION HEALTH FOUNDATION (US) | 1998-08-11 | — | — | US | claimed |
| US-4728673-A | BLOWING AGENT OF ISATOIC ANHYDRIDE DERIVATIVE IN PRESCENT OF NEUTRAL SALT | BAYER AKTIENGESELLSCHAFT (DE) | 1988-03-01 | — | — | US | claimed |
| US-4306074-A | Preparation of a mixture of an alkyl 3-chloroanthranilate and an alkyl 6-chloroanthranilate | BASF AKTIENGESELLSCHAFT (DE) | 1981-12-15 | — | — | US | claimed |
| EP-0020969-A1 | Process for the preparation of a mixture of 3-chloro-anthranilic acid alkyl ester and 6-chloro-anthranilic acid alkyl ester | BASF Aktiengesellschaft (DE) | 1981-01-07 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252009-A1 | BENZODIAZEPINE DERIVATIVE AND METHOD OF PRODUCING THE SAME | GABRA5, GABRA2, GABRA4 | LMNA 772/4885CYP1A2 316/4885ADRA2A 692/4885 |
| US-20120009226-A1 | HIGHLY PURE LAQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TLR7, MYD88, PDE7A | LMNA 1496/4885CYP1A2 211/4885ADRA2A 2074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.